1. Bilezikian J.P. et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. // J. bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2011. Vol. 26, № 10. P. 2317– 2337. 2. Brown E.M. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. // Physiol. Rev. United States, 1991. Vol. 71, № 2. P. 371–411. 3. Ferment O., Garnier P.E., Touitou Y. Comparison of the feedback effect of magnesium and calcium on parathyroid hormone secretion in man. // J. Endocrinol. England, 1987. Vol. 113, № 1. P. 117–122. 4. Inaba M. et al. Magnesium deficiency enhances secretion of parathyroid hormone in normal and 5/6-nephrectomized uremic rats. // J. Endocrinol. Invest. Italy, 1992. Vol. 15, № 9 Suppl 6. P. 135–142. 5. Quitterer U. et al. Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. // J. Biol. Chem. United States, 2001. Vol. 276, № 9. P. 6763– 6769. 6. Мирная С.С. et al. Роль кальций-чувствительного рецептора в поддержании системы кальциевого гомеостаза. 2010. P. 32–36. 7. Maeda S.S. et al. Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian Society of Endocrinology and Metabolism // Arch. Endocrinol. Metab. 2018. Vol. 62, № 1. P. 106–124. 8. Stack B.C. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Postoperative Hypoparathyroidism - Definitions and Management // Endocr. Pract. 2015. Vol. 21, № 6. P. 674–685. 9. Lorente-Poch L. et al. Defining the syndromes of parathyroid failure after total thyroidectomy // Gland Surg. 2015. Vol. 4, № 1. P. 82–90. 10. Grodski S., Serpell J. Evidence for the role of perioperative PTH measurement after total thyroidectomy as a predictor of hypocalcemia // World J. Surg. 2008. Vol. 32, № 7. P. 1367– 1373. 11. Lorente-Poch L. et al. Importance of in situ preservation of parathyroid glands during total thyroidectomy // Br. J. Surg. 2015. Vol. 102, № 4. 71 12. Clarke B.L. et al. Epidemiology and diagnosis of hypoparathyroidism // J. Clin. Endocrinol. Metab. 2016. Vol. 101, № 6. P. 2284–2299. 13. Kim J.H. et al. Diverse genetic aetiologies and clinical outcomes of paediatric hypoparathyroidism // Clin. Endocrinol. (Oxf). 2015. Vol. 83, № 6. P. 790–796. 14. Powers J. et al. Prevalence and incidence of hypoparathyroidism in the United States Using a large claims database // J. Bone Miner. Res. 2013. Vol. 28, № 12. P. 2570–2576. 15. Cutolo M. Autoimmune polyendocrine syndromes // Autoimmun. Rev. 2014. Vol. 13, № 2. P. 85–89. 16. Orlova E.M. et al. Autoimmune polyglandular syndrome type 1 in Russian patients: Clinical variants and autoimmune regulator mutations // Horm. Res. Paediatr. 2010. Vol. 73, № 6. P. 449–457. 17. Brown E.M. et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. // Nature. England, 1993. Vol. 366, № 6455. P. 575–580. 18. Grigorieva I. V., Thakker R. V. Transcription factors in parathyroid development: Lessons from hypoparathyroid disorders // Ann. N. Y. Acad. Sci. 2011. Vol. 1237, № 1. P. 24–38. 19. Veronese F.M. et al. A comparison of three fluorophores (ThT, ANS, bis-ANS) for the detection of amyloid fibers and prefibrillar oligomeric assemblies // Clin. Orthop. Relat. Res. 2015. Vol. 22, № 4. P. 244–258. 20. Goldmuntz E. DiGeorge syndrome: New insights // Clin. Perinatol. 2005. Vol. 32, № 4. P. 963–978. 21. Hannah M. Genetic developments in hypoparathyroidism For personal use only . Reproduce with permission from The Lancet Publishing Group . 2001. Vol. 357. P. 974–976. 22. S.A. S. et al. A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features // Arch. Dis. Child. 1991. Vol. 66, № 2. P. 193–196. 23. Blaine J., Chonchol M., Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. // Clin. J. Am. Soc. Nephrol. 2015. Vol. 10, № 7. P. 1257–1272. 24. Schlingmann K.P. et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TPRM6, a new member of the TPRM gene family // Nat. Genet. 2002. Vol. 31, № 2. P. 166–170. 25. Walder R.Y. et al. Mutation of TPRM6 causes familial hypomagnesemia with secondary hypocalcemia // Nat. Genet. 2002. Vol. 31, № 2. P. 171–174. 26. Pearce S.H.S. et al. A Familial Syndrome of Hypocalcemia with Hypercalciuria Due to 72 Mutations in the Calcium-Sensing Receptor // N. Engl. J. Med. 2002. Vol. 335, № 15. P. 1115–1122. 27. Weber S. et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis // J. Am. Soc. Nephrol. JASN. 2001. Vol. 12, № 9. P. 1872–1881. 28. Konrad M. et al. CLDN16 Genotype Predicts Renal Decline in Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis // J. Am. Soc. Nephrol. 2007. Vol. 19, № 1. P. 171–181. 29. Saeed A. et al. Sarcoidosis presenting with severe hypocalcaemia // Ir. J. Med. Sci. 2011. Vol. 180, № 2. P. 575–577. 30. Anderson T.J., Ewen S.W.B. Amyloid in normal and pathological parathyroid glands // J. Clin. Pathol. 1974. Vol. 27, № 8. P. 656–663. 31. T. Y. et al. Clinical case seminar: Riedel’s thyroiditis - Report of a case complicated by spontaneous hypoparathyroidism, recurrent laryngeal nerve injury, and Horner’s syndrome // J. Clin. Endocrinol. Metab. 2002. Vol. 87, № 8. P. 3543–3547. 32. Horwitz C.A., Myers W.P.L., Foote F.W. Secondary malignant tumors of the parathyroid glands. Report of two cases with associated hypoparathyroidism // Am. J. Med. 1972. Vol. 52, № 6. P. 797–808. 33. Shoback D. Clinical practice. Hypoparathyroidism. // N. Engl. J. Med. United States, 2008. Vol. 359, № 4. P. 391–403. 34. Glazebrook G.A. Effect of decicurie doses of radioactive iodine 131 on parathyroid function // Am. J. Surg. 1987. Vol. 154, № 4. P. 368–373. 35. Winslow C.P., Meyers A.D. Hypocalcemia as a complication of radioiodine therapy // Am. J. Otolaryngol. - Head Neck Med. Surg. 1998. Vol. 19, № 6. P. 401–403. 36. Guven A. et al. Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer // Ann. Nucl. Med. 2009. Vol. 23, № 5. P. 437–441. 37. Carpenter T.O., Carnes D.L., Anast C.S. Hypoparathyroidism in Wilson’s Disease // N. Engl. J. Med. 2010. Vol. 309, № 15. P. 873–877. 38. Joshi P., Lele V., Kapoor J. Dual ectopic thyroid - noninvasive diagnosis on radionuclide thyroid scan with SPECT/CT correlation: A case report and brief review of literature // Indian J. Endocrinol. Metab. 2013. Vol. 17, № 2. P. 359. 39. Belhoul K.M. et al. Serum ferritin levels and endocrinopathy in medically treated patients 73 with β thalassemia major // Ann. Hematol. 2012. Vol. 91, № 7. P. 1107–1114. 40. Angelopoulos N.G. et al. Hypoparathyroidism in transfusion-dependent patients with βthalassemia // J. Bone Miner. Metab. 2006. Vol. 24, № 2. P. 138–145. 41. Aleem A. et al. Hypocalcemia due to hypoparathyroidism in β-thalassemia major patients // Ann. Saudi Med. 2000. Vol. 20, № 5–6. P. 364–366. 42. Astor M.C. et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway // J. Clin. Endocrinol. Metab. 2016. Vol. 101, № 8. P. 3045–3053. 43. Underbjerg L. et al. The epidemiology of nonsurgical hypoparathyroidism in Denmark: A nationwide case finding study // J. Bone Miner. Res. 2015. Vol. 30, № 9. P. 1738–1744. 44. Rosato L. et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. // World J. Surg. 2004. Vol. 28, № 3. P. 271–276. 45. Underbjerg L. et al. Postsurgical hypoparathyroidism-Risk of fractures, Psychiatric Diseases, Cancer, Cataract, and Infections // J. Bone Miner. Res. 2014. Vol. 29, № S1. P. 2504–2510. 46. Davies L., Welch H.G. Current thyroid cancer trends in the United States // JAMA Otolaryngol. - Head Neck Surg. 2014. Vol. 140, № 4. P. 317–322. 47. Underbjerg L., Sikjaer T., Rejnmark L. Long-Term Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study // J. Bone Miner. Res. 2018. Vol. 33, № 5. P. 822–831. 48. Cianferotti L. Classification of Hypoparathyroid Disorders // Front. Horm. Res. 2018. Vol. 51. P. 127–138. 49. FRANKENHAEUSER B., HODGKIN A.L. The action of calcium on the electrical properties of squid axons. // J. Physiol. 1957. Vol. 137, № 2. P. 218–244. 50. Chou C.T., Siegel B., Mehta D. Stridor and apnea as the initial presentation of primary hypoparathyroidism // Int. J. Pediatr. Otorhinolaryngol. Elsevier Ireland Ltd, 2016. Vol. 80. P. 30–32. 51. Fong J., Khan A. Hypocalcemia: updates in diagnosis and management for primary care. // Can. Fam. Physician. 2012. Vol. 58, № 2. P. 158–162. 52. Mitchell D.M. et al. Long-term follow-up of patients with hypoparathyroidism // J. Clin. Endocrinol. Metab. 2012. Vol. 97, № 12. P. 4507–4514. 53. Goswami R. et al. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism // Clin. Endocrinol. 74 (Oxf). 2012. Vol. 77, № 2. P. 200–206. 54. ABE S. et al. A Rare Case of Idiopathic Hypoparathyroidism with Varied Neurological Manifestations. // Intern. Med. 2008. Vol. 35, № 2. P. 129–134. 55. Aggarwal S. et al. Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium // Eur. J. Endocrinol. 2013. Vol. 168, № 6. P. 895–903. 56. Vered I. et al. Normal left ventricular performance documented by doppler echocardiography in patients with long-standing hypocalcemia // Am. J. Med. 1989. Vol. 86, № 4 C. P. 413–416. 57. Gosmanova E.O. et al. Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. // Adv. Ther. 2021. Vol. 38, № 8. P. 4246–4257. 58. Newman D.B. et al. Reversible cardiac dysfunction associated with hypocalcemia: A systematic review and meta-analysis of individual patient data // Heart Fail. Rev. 2014. Vol. 19, № 2. P. 199–205. 59. Levy I. et al. The impact of hypoparathyroidism treatment on the kidney in children: Longterm retrospective follow-up study // J. Clin. Endocrinol. Metab. 2015. Vol. 100, № 11. P. 4106–4113. 60. Cusano N.E., Bilezikian J.P. Signs and Symptoms of Hypoparathyroidism. // Endocrinol. Metab. Clin. North Am. United States, 2018. Vol. 47, № 4. P. 759–770. 61. M.L. M. et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density // BMC Endocr. Disord. 2013. Vol. 13. P. 1. 62. Chawla H. et al. Vertebral Fractures and Bone Mineral Density in Patients With Idiopathic Hypoparathyroidism on Long-Term Follow-Up // J. Clin. Endocrinol. Metab. 2016. Vol. 102, № 1. P. 251–258. 63. Jakkani R.K., Sureka J., Mathew J. Spondyloarthropathy occurring in long-standing idiopathic hypoparathyroidism // Radiol. Case Reports. The Authors., 2015. Vol. 6, № 4. P. 545. 64. Dai C.L. et al. Elevated muscle enzymes and muscle biopsy in idiopathic hypoparathyroidism patients // J. Endocrinol. Invest. 2012. Vol. 35, № 3. P. 286–289. 65. Jensen S.B.O.R.G.L.U.M., Illum F., Dupont E. Nature and frequency of dental changes in 75 idiopathic hypoparathyroidism and p s eudohypop ar athy r oidi sm. 66. Srirangarajan S. et al. Dental manifestation of primary idiopathic hypoparathyroidism // J. Indian Soc. Periodontol. 2014. Vol. 18, № 4. P. 524–526. 67. STEINBERG H., WALDRON B.R. Idiopathic hypoparathyroidism; an analysis of fiftytwo cases, including the report of a new case. // Medicine (Baltimore). United States, 1952. Vol. 31, № 2. P. 133–154. 68. Arlt W. et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D // Eur. J. Endocrinol. 2002. Vol. 146, № 2. P. 215–222. 69. Saha S. et al. Long-term outcome of cataract surgery in patients with idiopathic hypoparathyroidism and its relationship with their calcemic status // J. Bone Miner. Metab. Springer Japan, 2017. Vol. 35, № 4. P. 405–411. 70. Ayuk J. et al. Case report A blind panic // Lancet. 2001. Vol. 357. P. 1262. 71. Das K. et al. Mucocutaneous manifestations of acquired hypoparathyroidism: An observational study // Indian J. Endocrinol. Metab. 2012. Vol. 16, № 5. P. 819. 72. Margarida C., Cruz S. A Case of Acute Generalized Pustular Psoriasis of von Zumbusch Triggered by Hypocalcemia. 2015. Vol. 000. P. 345–351. 73. Hannan F.M., Thakker R. V. Investigating hypocalcaemia // BMJ. 2013. Vol. 346, № 7911. P. 1–4. 74. Bollerslev J. et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults // Eur. J. Endocrinol. Bristol, UK: Bioscientifica Ltd, 2015. Vol. 173, № 2. 75. Khan A.A. et al. Standards of care for hypoparathyroidism in adults: A Canadian and international consensus // Eur. J. Endocrinol. 2019. Vol. 180, № 3. P. P1–P22. 76. Shoback D.M. et al. Presentation of hypoparathyroidism: Etiologies and clinical features // J. Clin. Endocrinol. Metab. 2016. Vol. 101, № 6. P. 2300–2312. 77. Vokes T. et al. Hypoparathyroidism // Prim. Metab. Bone Dis. Disord. Miner. Metab. 2018. Vol. 51. P. 654–660. 78. Meola A. et al. Efficacy and safety of long-term management of patients with chronic postsurgical hypoparathyroidism // J. Endocrinol. Invest. Springer International Publishing, 2018. Vol. 41, № 10. P. 1221–1226. 79. Asari R. et al. Hypoparathyroidism After Total Thyroidectomy. 2015. Vol. 143, № 2. P. 76 132–137. 80. Edafe O. et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia // Br. J. Surg. 2014. Vol. 101, № 4. P. 307–320. 81. Selberherr A. et al. Postoperative hypoparathyroidism after thyroidectomy: Efficient and cost-effective diagnosis and treatment // Surg. (United States). Elsevier Inc., 2015. Vol. 157, № 2. P. 349–353. 82. Abbas A. Diagnosis and management of hypocalcaemia in adults // Endocrinol. Diabetes Case Stud. Quest. Comment. 2015. P. 133–140. 83. Hadker N. et al. Understanding the Burden of Illness Associated with Hypoparathyroidism Reported Among Patients in the Paradox Study // Endocr. Pract. 2014. Vol. 20, № 7. P. 671–679. 84. Brandi M.L. et al. Management of hypoparathyroidism: Summary statement and guidelines // J. Clin. Endocrinol. Metab. 2016. Vol. 101, № 6. P. 2273–2283. 85. Maeda. Hypoparathyroidism and Pseudohypoparathyroidism HYPOCALCEMIA: CLINICAL MANIFESTATIONS AND DIFFERENTIAL DIAGNOSIS. 2006. Vol. 50. 86. Webster A.C. et al. Chronic Kidney Disease // Lancet. Elsevier Ltd, 2017. Vol. 389, № 10075. P. 1238–1252. 87. Broughton P.M. et al. Diurnal variations in serum biochemical and haematological measurements. // J. Clin. Pathol. 2007. Vol. 42, № 2. P. 172–179. 88. Agus Z. DISEASE OF THE MONTH: Hypomagnesemia. 1999. № 151. P. 1616–1622. 89. Pearce S.H.S., Cheetham T.D. Diagnosis and management of vitamin D deficiency // BMJ. 2010. Vol. 340, № 7738. P. 142–147. 90. Kihara M. et al. Recovery of Parathyroid Function After Total Thyroidectomy // Surg. Today. 2003. Vol. 30, № 4. P. 0333–0338. 91. Boyce A.M. et al. Ultrasound is Superior to Computed Tomography for Assessment of Medullary Nephrocalcinosis in. 2013. Vol. 98, № March. P. 989–994. 92. Colombo G., Solbiati M. Ultrasonography versus computed tomography for suspected nephrolithiasis // Intern. Emerg. Med. 2015. Vol. 10, № 4. P. 515–516. 93. Underbjerg L. et al. Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study // J. Bone Miner. Res. 2013. Vol. 28, № 11. P. 2277–2285. 94. Sorensen M.D. et al. In-Office Ultrasound Facilitates Timely Clinical Care at a 77 Multidisciplinary Kidney Stone Center. // Urol. Pract. 2020. Vol. 7, № 3. P. 167–173. 95. Sternberg K.M., Littenberg B. Trends in Imaging Use for the Evaluation and Followup of Kidney Stone Disease: A Single Center Experience. // J. Urol. United States, 2017. Vol. 198, № 2. P. 383–388. 96. Valencia V. et al. Study of Tomography Of Nephrolithiasis Evaluation (STONE): methodology, approach and rationale. // Contemp. Clin. Trials. United States, 2014. Vol. 38, № 1. P. 92–101. 97. Brisbane W., Bailey M.R., Sorensen M.D. An overview of kidney stone imaging techniques. // Nat. Rev. Urol. 2016. Vol. 13, № 11. P. 654–662. 98. Andrabi Y. et al. Advances in CT imaging for urolithiasis. // Indian J. Urol. 2015. Vol. 31, № 3. P. 185–193. 99. Carter M.R., Green B.R. Renal calculi: emergency department diagnosis and treatment. // Emerg. Med. Pract. United States, 2011. Vol. 13, № 7. P. 1–17; quiz 18. 100. Ather M.H. Non-contrast CT in the Evaluation of Urinary Tract Stone Obstruction and Haematuria / ed. Memon W. Rijeka: IntechOpen, 2017. P. Ch. 5. 101. Ковалева Е.В. Хронический гипопаратиреоз: предикторы развития осложнений заболевания и персонализация ведения пациентов. 2022. 189 p. 102. Kovaleva E. V. et al. The Russian Registry of Chronic Hypoparathyroidism // Front. Endocrinol. (Lausanne). 2022. Vol. 13, № February. P. 1–11. 103. Petrarca M. et al. A case of brain calcifications in postsurgical hypoparathyroidism // Intern. Emerg. Med. Springer Milan, 2017. Vol. 12, № 1. P. 113–115. 104. Seedat F., Daya R., Bhana S.A. Hypoparathyroidism Causing Seizures: When Epilepsy Does Not Fit // Case Rep. Med. Hindawi, 2018. Vol. 2018, № Figure 3. P. 1–4. 105. Takamura Y., Miyauchi A. Attenuation of Postmenopausal Bone Loss in Patients with Transient Hypoparathyroidism After Total Thyroidectomy. 2013. P. 2860–2865. 106. Silva B.C. et al. Bone imaging in hypoparathyroidism // Osteoporos. Int. Osteoporosis International, 2016. 107. Rubin M.R. et al. Dynamic and Structural Properties of the Skeleton in Hypoparathyroidism. 2018. Vol. 23, № 12. P. 2018–2024. 108. Chen Q. et al. Effects of an Excess and a Deficiency of Endogenous Parathyroid Hormone on Volumetric Bone Mineral Density and Bone Geometry Determined by Peripheral Quantitative Computed Tomography in Female Subjects. 2015. Vol. 88, № November. P. 78 4655–4658. 109. Bruserud Ø. et al. polyendocrine syndrome type 1. 2016. № June. P. 1–10. 110. Meager A. et al. Anti-cytokine autoantibodies in autoimmunity : preponderance of neutralizing autoantibodies against interferon-alpha , interferon-omega and interleukin-12 in patients with thymoma and / or myasthenia gravis. 2003. P. 128–136. 111. Meloni A. et al. Autoantibodies against Type I Interferons as an Polyendocrine Syndrome Type I. 2015. Vol. 93, № November 2008. P. 4389–4397. 112. Sozaeva L.S. Новые иммунологические методы диагностики аутоиммунного полиэндокринного синдрома 1-го типа. 2015. P. 43–46. 113. Zhang J. et al. A Functional Alternative Splicing Mutation in AIRE Gene Causes Autoimmune Polyendocrine Syndrome Type 1. 2013. Vol. 8, № 1. P. 1–6. 114. Rathod A. et al. Association of urinary calcium excretion with serum calcium and vitamin D levels // Clin. J. Am. Soc. Nephrol. 2015. Vol. 10, № 3. P. 452–462. 115. Rodríguez-Ortiz M.E. et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration // Nephrol. Dial. Transplant. 2014. Vol. 29, № 2. P. 282–289. 116. Mutnuri S., Fernandez I., Kochar T. Suppression of Parathyroid Hormone in a Patient with Severe Magnesium Depletion // Case Reports Nephrol. 2016. Vol. 2016. P. 1–3. 117. Streeten E.A. et al. Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol. // J. Clin. Endocrinol. Metab. 2017. Vol. 102, № 5. P. 1505–1510. 118. Holick M.F., Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. // Am. J. Clin. Nutr. United States, 2008. Vol. 87, № 4. P. 1080S-6S. 119. Holick M.F. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. // Rev. Endocr. Metab. Disord. Germany, 2017. Vol. 18, № 2. P. 153–165. 120. Bischoff-Ferrari H.A. et al. Estimation of optimal serum concentrations of 25- hydroxyvitamin D for multiple health outcomes // Am. J. Clin. Nutr. 2006. Vol. 84, № 1. P. 18–28. 121. Bilezikian J.P. et al. Management of hypoparathyroidism: Present and future // J. Clin. Endocrinol. Metab. 2016. Vol. 101, № 6. P. 2313–2324. 122. Ковалева Е.В., Еремкина А.К. М.Н.Г. Суточный профиль как диагностический инструмент выявления гипо- и гиперкальциемии у пациентов с хроническим 79 гипопаратиреозом. Серия клинических случаев // Ожирение и метаболизм. 2021. Vol. Т.18, № №2. P. 175–179. 123. Li D.-F. et al. Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis // J. Transl. Med. 2020. Vol. 18, № 1. P. 106. 124. Santos F. Hypercalciuria Associated With Long-term Administration of Calcitriol (1,25- Dihydroxyvitamin D3) // Am. J. Dis. Child. 2011. Vol. 140, № 2. P. 139. 125. Bilezikian J.P. et al. Management of Hypoparathyroidism: Present and Future. // J. Clin. Endocrinol. Metab. 2016. Vol. 101, № 6. P. 2313–2324. 126. Porter R.H. et al. Treatment of hypoparathyroid patients with chlorthalidone. // N. Engl. J. Med. United States, 1978. Vol. 298, № 11. P. 577–581. 127. Khan M., Waguespack S., Hu M. Medical Management of Postsurgical Hypoparathyroidism // Endocr. Pract. 2010. Vol. 17, № Supplement 1. P. 18–25. 128. Fujita T. Comparative Efficacy of Various Vitamin D Metabolites. 2015. Vol. 1982, № 55. P. 238–243. 129. Straub D.A. Calcium supplementation in clinical practice: A review of forms, doses, and indications // Nutr. Clin. Pract. 2007. Vol. 22, № 3. P. 286–296. 130. Davies M. et al. 1,25-dihydroxycholecalciferol in hypoparathyroidism // Lancet (London, England). 1977. Vol. 1, № 8002. P. 55—59. 131. HILL L.F. et al. Treatment of Hypoparathyroidism With 1,25‐Dihydroxycholecalciferol // Clin. Endocrinol. (Oxf). 1976. Vol. 5. P. s167–s173. 132. Kanis J.A., Smith R.G.G.R.A.N.D.R. BETWEEN VITAMIN D , ITS METABOLITES A N D A N A L O G U E S. 1977. Vol. 3. P. 191–201. 133. Klein R. et al. The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF CHICAGO LIBRARIES on August 20, 2013. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights. 1981. 134. Kurzel R.B., Hagen G.A. Use of Thiazide Diuretics to Reduce the Hypercalciuria of Hypoparathyroidism During Pregnancy // Am. J. Perinatol. 1990. Vol. 7, № 4. P. 333–336. 135. Newman G.H., Wade M., Hosking D.J. Effect of bendrofluazide on calcium reabsorption in hypoparathyroidism // Eur. J. Clin. Pharmacol. 1984. Vol. 27, № 1. P. 41–46. 136. Parfitt A.M. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. // Ann. Intern. Med. 1972. Vol. 77, № 4. P. 557–563. 80 137. Murdoch D. et al. A comparison of the potassium and magnesium‐sparing properties of amiloride and spironolactone in diuretic‐treated normal subjects. // Br. J. Clin. Pharmacol. 1993. Vol. 35, № 4. P. 373–378. 138. Santos F., Smith M.J., Chan J.C. Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. // Am. J. Dis. Child. United States, 1986. Vol. 140, № 2. P. 139–142. 139. J.B. C.-A., M. R.-G. Hyperphosphataemia as a cardiovascular risk factor - How to manage the problem // Nephrol. Dial. Transplant. 2002. Vol. 17, № SUPPL. 11. P. 16–19. 140. Bandeira L.C. et al. Vitamin D and Hypoparathyroidism // Front. Horm. Res. 2018. Vol. 50. P. 114–124. 141. Клинические Рекомендации Российской Ассоциации Эндокринологов По Диагностике, Лечению И Профилактике Дефицита Витамина D У Взрослых // Проблемы Эндокринологии. 2016. Vol. 62, № 4. 142. Winer K.K. et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. // J. Clin. Endocrinol. Metab. United States, 2003. Vol. 88, № 9. P. 4214–4220. 143. Winer K.K. et al. A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1–34 in Treatment of Hypoparathyroidism // J. Clin. Endocrinol. Metab. 1998. Vol. 83, № 10. P. 3480–3486. 144. Winer K.K. et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. // J. Clin. Endocrinol. Metab. 2008. Vol. 93, № 9. P. 3389–3395. 145. Winer K.K. et al. Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism // J. Pediatr. Elsevier Inc., 2018. Vol. 203. P. 391-399.e1. 146. Avsievich E.S. et al. Dihydrotachysterol: a Bad Choice in the Treatment of Chronic Hypoparathyroidism // Obe. Metab. 2022. Vol. 19, № 2. P. 198–205. 147. Jensterle M. et al. Dihydrotachysterol intoxication treated with pamidronate: a case report // Cases J. 2010. Vol. 3, № 1. P. 78. 148. Quack I. et al. Dihydrotachysterol therapy for hypoparathyroidism: consequences of inadequate monitoring. Five cases and a review. // Exp. Clin. Endocrinol. diabetes Off. journal, Ger. Soc. Endocrinol. [and] Ger. Diabetes Assoc. Germany, 2005. Vol. 113, № 7. P. 376–380. 81 149. Jalbert M. et al. [Severe hypercalcemia of unusual cause, looking for the culprit: Case report and review of the literature]. // Nephrol. Ther. France, 2018. Vol. 14, № 4. P. 231–236. 150. Erbil Y. et al. Determinants of postoperative hypocalcemia in vitamin D-deficient Graves’ patients after total thyroidectomy // Am. J. Surg. Elsevier Inc., 2011. Vol. 201, № 5. P. 685– 691. 151. Erbil Y. et al. The impact of age, vitamin D3 level, and incidental parathyroidectomy on postoperative hypocalcemia after total or near total thyroidectomy // Am. J. Surg. 2009. Vol. 197, № 4. P. 439–446. 152. Erbil Y. et al. Predictive value of age and serum parathormone and vitamin d3 levels for postoperative hypocalcemia after total thyroidectomy for nontoxic multinodular goiter. // Arch. Surg. United States, 2007. Vol. 142, № 12. P. 1182–1187. 153. Hypocalcemia P., Thyroidectomy A. Does Preoperative Vitamin D Deficiency Predict. 2018. Vol. 23, № 1. P. 5–9. 154. Unsal I.O. et al. Preoperative Vitamin D Levels as a Predictor of Transient Hypocalcemia and Hypoparathyroidism After Parathyroidectomy // Sci. Rep. 2020. Vol. 10, № 1. P. 9895. 155. de Carvalho G.B. et al. Preoperative vitamin D deficiency is a risk factor for postoperative hypocalcemia in patients undergoing total thyroidectomy: Retrospective cohort study // Sao Paulo Med. J. 2019. Vol. 137, № 3. P. 241–247. 156. Malik M.Z. et al. Role of Preoperative Administration of Vitamin D and Calcium in Postoperative Transient Hypocalcemia after Total Thyroidectomy. // Cureus. 2019. Vol. 11, № 4. P. e4579. 157. Kirkby-Bott J. et al. Preoperative vitamin D deficiency predicts postoperative hypocalcemia after total thyroidectomy. // World J. Surg. United States, 2011. Vol. 35, № 2. P. 324–330. 158. Chang Y.K., Lang B.H.H. To identify or not to identify parathyroid glands during total thyroidectomy // Gland Surg. 2017. Vol. 6, № S1. P. S20–S29. 159. Hallgrimsson P. et al. Risk factors for medically treated hypocalcemia after surgery for Graves’ disease: A swedish multicenter study of 1,157 patients // World J. Surg. 2012. Vol. 36, № 8. P. 1933–1942. 160. Bergenfelz A. et al. Complications to thyroid surgery: Results as reported in a database from a multicenter audit comprising 3,660 patients // Langenbeck’s Arch. Surg. 2008. Vol. 393, № 5. P. 667–673. 161. Alhefdhi A., Mazeh H., Chen H. Role of Postoperative Vitamin D and/or Calcium Routine 82 Supplementation in Preventing Hypocalcemia After Thyroidectomy: A Systematic Review and Meta-Analysis // Oncologist. 2013. Vol. 18, № 5. P. 533–542. 162. Grzegory A., Pomorski L. Perioperative calcium and vitamin D supplementation in patients undergoing thyroidectomy – literature review // Polish J. Surg. 2018. Vol. 90, № 4. P. 34– 38. 163. Bai B., Chen Z., Chen W. Risk factors and outcomes of incidental parathyroidectomy in thyroidectomy: A systematic review and meta-analysis // PLoS One. 2018. Vol. 13, № 11. P. 1–17. 164. Cui Q. et al. A prospective cohort study of novel functional types of parathyroid glands in thyroidectomy // Medicine (Baltimore). 2016. Vol. 95, № 52. P. e5810. 165. Oran E. et al. The risk of hypocalcemia in patients with parathyroid autotransplantation during thyroidectomy // Turkish J. Surg. 2015. Vol. 32, № 1. P. 6–10. 166. Husebye E.S. et al. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type i // J. Intern. Med. 2009. Vol. 265, № 5. P. 514–529. 167. Husebye E.S., Anderson M.S., Kämpe O. Autoimmune Polyendocrine Syndromes // N. Engl. J. Med. 2018. Vol. 378, № 12. P. 1132–1141. 168. Li Y. et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism // J. Clin. Invest. 1996. Vol. 97, № 4. P. 910– 914. 169. Kemp E.H. et al. Prevalence and clinical associations of calcium-sensing receptor and NALP5 autoantibodies in finnish APECED patients // J. Clin. Endocrinol. Metab. 2014. Vol. 99, № 3. P. 1064–1071. 170. Kifor O. et al. A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor // J. Clin. Endocrinol. Metab. 2003. Vol. 88, № 1. P. 60–72. 171. Alimohammadi M. et al. Autoimmune Polyendocrine Syndrome Type 1 and NALP5, a Parathyroid Autoantigen // N. Engl. J. Med. 2008. Vol. 358, № 10. P. 1018–1028. 172. Meloni A. et al. Autoimmune polyendocrine syndrome type 1: An extensive longitudinal study in Sardinian patients // J. Clin. Endocrinol. Metab. 2012. Vol. 97, № 4. P. 1114–1124. 173. Meager A. et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1 // PLoS Med. 2006. Vol. 3, № 7. P. 1152–1164.